Kirkland, Polsinelli Rep Akorn In $640M Hi-Tech Pharma Buy

Law360, New York (August 27, 2013, 12:48 PM EDT) -- Akorn Inc. said on Tuesday that it will buy Long Island, N.Y.-based Hi-Tech Pharmacal Co. Inc. for $640 million, a move that the niche pharmaceutical company hopes will bolster its hold on the generic eye medication market and broaden its offerings with hard-to-make over-the-counter and prescription drugs.

The deal values Hi-Tech shares at $43.50 a pop, a 23.5 percent premium on Thursday's closing price. Akorn plans to fund the acquisition with $600 million in loan borrowings and cash assumed from Hi-Tech — as of April 30,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.